Trials in Ohio.

This trial tested bapineuzumab, an infused antibody designed to bind and clear beta amyloid from the brain, against a placebo. It measured whether it helped…

This trial tested whether bapineuzumab, an antibody given by infusion that helps clear beta amyloid from the brain, could affect thinking and daily function in…

This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…

This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…

This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…

This study tests whether a focused-ultrasound device, guided by MRI, can safely and temporarily open the blood-brain barrier in people with probable…

This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…

This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…

CYCLE-AD is testing whether long-term, high-intensity indoor cycling on a home-based Peloton bike can slow or delay cognitive decline and Alzheimer's-related…

This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…

This trial tests sabirnetug, an antibody given by IV infusion every four weeks, against placebo. It looks at whether the drug slows decline in thinking and…

This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…

This Phase 3 trial tested rosiglitazone XR, a diabetes drug already approved for type 2 diabetes, as a standalone treatment for mild to moderate Alzheimer's…

This Phase 3 trial tested rosiglitazone XR, a diabetes drug, in people with mild-to-moderate Alzheimer's disease. It was an open-label extension study, meaning…

This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. It looked at how well the…

This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. Researchers measured safety…

This trial tested SB-742457, an experimental drug added on top of donepezil, the standard Alzheimer's medication, in people with mild-to-moderate Alzheimer's…

This trial looked at the long-term safety and tolerability of bapineuzumab, an antibody drug given by infusion, in people with Alzheimer's who had finished an…

This trial tests whether a more precise form of whole-brain radiation can spare the hippocampus, the brain's memory center, in people whose cancer has spread…

Enroll-HD is an observational study, meaning no drug or treatment is given. It follows people with Huntington's disease, and their relatives and controls,…

This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…

This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…

This is an observational study, so nothing is being tested as a treatment. Researchers are looking at how the genes and symptoms of ALS and related conditions,…

This Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a…

This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…

This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…

This study looks at how Alzheimer's disease, Lewy body dementia, and Parkinson's disease differ from one another. Researchers use brain scans (DaTscan, amyloid…

This is a biorepository project, not a treatment trial. Researchers are collecting medical records and biological samples (like blood or tissue) from people…

This Phase 3 trial is testing whether escitalopram, a common antidepressant, can safely reduce agitation in people who already have Alzheimer's dementia. Phase…

This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…

This trial is testing whether extended-release metformin, a widely used diabetes drug, can slow memory decline in people who are overweight and already showing…

This trial tests AMT-130, a gene therapy delivered by brain surgery into a deep brain region called the striatum, in adults with early Huntington's disease. It…

This trial is testing NYX-458, an experimental oral drug, against a placebo in people who have mild cognitive impairment or mild dementia caused by Parkinson's…

This is not a treatment trial. It is a study building a pool of adults with Down syndrome, ages 25 to 55, who are ready to be recruited into future Alzheimer's…

PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…

This is a large North American research registry and natural history study tracking people with frontotemporal lobar degeneration (FTLD) and related conditions…

This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…

The DISCOVERY study is an observational study — no drug or treatment is being tested. Researchers are following stroke survivors over time, collecting…

This trial tests donanemab, an anti-amyloid antibody given by infusion, against a placebo in people with no memory or thinking problems but signs of amyloid in…

This trial is testing whether a gene therapy that delivers a brain-protective protein called BDNF directly into the brain can slow cell loss in people with…

This trial is testing whether masupirdine, a daily pill, can ease agitation in people who already have Alzheimer's dementia. Agitation can mean restlessness,…

This Phase 2 trial is testing BIIB080, a drug injected into the spinal fluid, to see whether it can slow cognitive decline in people with mild cognitive…

This Phase 3 trial is testing remternetug, an anti-amyloid antibody given by IV or injection under the skin, in people with early symptomatic Alzheimer's…

This Phase 3 trial is testing KarXT, an oral drug, to see whether it prevents the return of psychosis symptoms — hallucinations and delusions — in people who…

This trial tests whether a pill called AR1001 can slow memory and thinking decline in people with early Alzheimer's, compared with a placebo. It also checks…

This trial is testing CT1812, an experimental drug, in people with early Alzheimer's disease — either mild cognitive impairment or mild dementia confirmed by…

This trial tests a brain scan, not a treatment. A tracer called PI-2620 is given before a PET scan to show tau, a protein tied to Alzheimer's. Researchers…

This Phase 2 trial is testing whether a liquid oral combination of THC and CBD (the two main active compounds in cannabis) can reduce agitation in people with…

This trial tests two behavioral programs for African American women who are caregivers for someone living with dementia and who also have high blood pressure.…

This trial tests a computer-based program that teaches people to feel less alarmed by anxious sensations, such as a racing heart. It looks at whether anxiety…